Overview

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

Status:
Withdrawn
Trial end date:
2020-10-09
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of MEDI8852 for the treatment of influenza caused by a wild type A/H1N1 challenge strain in healthy, influenza serosusceptible adults.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
MEDI8852
Oseltamivir